A Study of Axitinib in Advanced Carcinoid Tumors
Model scores of the 29,894 trials active now.
Model score 38% for any early termination, 17% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 26% of the time (3,728 trials).
Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.
How it ended
Completed on 2018-02-13, after 2011-10-25 start.
The score above never used this outcome: finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.
Termination over time, as the model saw it at the start
Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2018-02-13. The rest of the way to 100% is still running.
From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.
What moved the score
-
Wording of the registration (title, summary, criteria) (raises risk) · Wording
Phrases that raised it: small cellstablepriorcompletedpatient
Phrases that lowered it: tractadvancedhepaticpulmonarymetastatic -
Sponsor's past termination rate: 47.5% (raises risk) · Sponsor's track record
-
Accepts healthy volunteers: No (raises risk) · Who can join
-
Phase: 2 (raises risk) · Design
-
Disease area, cancer: Yes (raises risk) · Disease area
-
Design: single group (raises risk) · Design
-
Sponsor type: academic or other (raises risk) · Sponsor's track record
-
Has a data monitoring committee: Yes (raises risk) · Design
-
Trials the sponsor started in the prior 2 years: 30 (lowers risk) · Sponsor's track record
-
Primary purpose: treatment (raises risk) · Design
-
Minimum age: 18 (raises risk) · Who can join
-
Maximum age: not given (raises risk) · Who can join
-
Blinding: none (raises risk) · Design
-
Collaborators: 2 (lowers risk) · Design
-
Drug's FAERS reports with a death: 20.7% (lowers risk) · Drug's FDA history
-
Keywords listed: 12 (raises risk) · Design
-
Number of arms: 1 (raises risk) · Design
-
Drug's FAERS reports in the prior 12 months: 57 (raises risk) · Drug's FDA history
Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.
The trial
Design
- Phase
- 2
- Number of arms
- 1 (typical: 2)
- Allocation
- not applicable (typical: randomized)
- Design
- single group (typical: parallel)
- Primary purpose
- treatment
- Blinding
- none
- Has a data monitoring committee
- Yes (typical: 56% yes)
- Responsible party
- sponsor
- Collaborators
- 2 (typical: 0)
- Keywords listed
- 12 (typical: 1)
Who can join
- Minimum age
- 18
- Maximum age
- not given (typical: 71)
- Sex
- all
- Accepts healthy volunteers
- No (typical: 9% yes)
Sponsor's track record
- Sponsor type
- academic or other
- Sponsor's past trials
- 59 (typical: 32)
- Sponsor's past termination rate
- 47.5% (typical: 9.9%)
- Trials the sponsor started in the prior 2 years
- 30 (typical: 19)
Drug's FDA history
- Drugs with FDA adverse-event history
- 2 (typical: 1)
- Drug has FAERS history
- Yes (typical: 64% yes)
- Drug's FAERS reports before start
- 237 (typical: 2148)
- Drug's FAERS reports in the prior 12 months
- 57 (typical: 412.5)
- Drug's FAERS reports marked serious
- 86.9% (typical: 85.6%)
- Drug's FAERS reports with a death
- 20.7% (typical: 15.9%)
Disease area and drugs
- Disease areas
- cancer
- Drugs matched to FDA substances
- axitinib, tyrosine
Typical values are among the trials active now. Sponsor and drug history are counted only up to this trial's start date.
Similar finished trials
- Sandostatin LAR and Axitinib vs Pbo in Pnts With Advanced Well-differentiated Non-pancreatic Neuroendocrine Carcinomas NCT01744249 · started 2011 · scored riskier than 86% of active trials completed
- Phase III Study of Surufatinib in Treating Advanced Extrapancreatic Neuroendocrine Tumors NCT02588170 · started 2015 · scored riskier than 80% of active trials completed
- Phase III Study of Surufatinib in Treating Advanced Pancreatic Neuroendocrine Tumors NCT02589821 · started 2015 · scored riskier than 81% of active trials completed
- Phase Ib/II Study of Sulfatinib in Treating Advanced Neuroendocrine Tumors NCT02267967 · started 2014 · scored riskier than 24% of active trials completed
- Cabozantinib in Advanced Pancreatic Neuroendocrine and Carcinoid Tumors NCT01466036 · started 2012 · scored riskier than 90% of active trials completed
Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.